1例胰腺癌伴重度肾功能不全血液透析患者的药学监护  

Pharmaceutical care for a pancreatic cancer patient with severe renal insufficiency undergoing hemodialysis

作　　者：王春晖[1] 石培琪 梅清华[2] 吴薇[1] WANG Chunhui;SHI Peiqi;MEI Qinghua;WU Wei(Zhongshan Hospital,Fudan University,Shanghai,200032,China;Guangdong Second Provincial General Hospital,Guangzhou,510317,Guangdong,China)

机构地区：[1]复旦大学附属中山医院,上海200032 [2]广东省第二人民医院,广东广州510317

出　　处：《肿瘤药学》2024年第1期100-103,共4页Anti-Tumor Pharmacy

基　　金：上海市“医苑新星”青年医学人才培养资助计划(沪卫人事[2022]65号);上海市临床重点专科项目(shslczdzk06504)。

摘　　要：目的探讨胰腺癌患者维持血液透析期间抗肿瘤治疗的可行性及治疗方案的选择。方法临床药师对1例胰腺癌患者维持血液透析期间化疗病例进行病情分析,并查阅文献,根据患者肾功能状态,协助医生制定合理的抗肿瘤方案。结果患者在接受吉西他滨或替吉奥单药个体化治疗后未出现严重不良反应,化疗结束后不适症状较前明显改善,肿瘤标志物较前下降。结论临床药师应积极参与胰腺癌患者维持血液透析期间个体化治疗方案的制定及实施,保障患者安全用药,为后续临床实践提供参考。Objective To investigate the feasibility of antitumor therapy and the choice of treatment options during main-tenance hemodialysis for patients with pancreatic cancer.Methods The clinical pharmacist analyzed the condition of a case of pancreatic cancer patient undergoing dialysis treated with chemotherapy,reviewed the literature and assisted the doctor to formulate reasonable anti-tumor regimen according to the patient's renal function.Results After given individualized treatment with single gemcitabine or S-1,the patient had obvious improvement in discomfort and a significant decrease in tumor markers compared to before.No serious adverse reactions were observed.Conclusion Clinical pharmacists should in-volve in the formulation and implementation of individualized treatment for pancreatic cancer patients during dialysis,so as to ensure the medication safety for patients and to provide reference for subsequent clinical practice.

关 键 词：胰腺癌 透析 化疗 肾功能不全 

分 类 号：R735.9[医药卫生—肿瘤] R969.3[医药卫生—临床医学]